// App-Quantinova.ai

6617 : Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials.

Researchers

Presenter

  • Meena Venkatachalam

Principal Investigators

  • David D. Stenehjem

  • Guilhem Pietri

  • John R. Penrod

  • Beata Korytowsky

Medical Centers

  • Parexel, Waltham, MA

  • Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01642004

  • NCT01673867

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved